BioSpace News Archive

London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, OrbiMed and Brace Pharma Capital.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134.

Company co-founder Mitch Finer named new Chairman of the Board

Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations

TD-1473 Advancing into Phase 2b/3 Study in Ulcerative Colitis in Fourth Quarter Following Completion of Phase 1b Study and Successful Dialogues with FDA and EMA

Company Announces New Members to Scientific Advisory Board

Newron Pharmaceuticals S.p.A. announced that Stefan Weber, CEO, will present at the Wedbush PacGrow Healthcare Conference in New York, NY, on Wednesday, August 15, 2018 at 1:20 p.m. ET.

Immunotherapy Focused Consulting Company Provides Independent Support of the Value of Daily Body Restore® for Cancer Patients

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2018.

The TAKE ON HEP C tour will travel to select events in 2018 and provide free hepatitis C testing and access to VA benefits counseling